14,138 Shares in Twist Bioscience Co. (NASDAQ:TWST) Acquired by Westwood Holdings Group Inc.

Westwood Holdings Group Inc. acquired a new stake in Twist Bioscience Co. (NASDAQ:TWST - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 14,138 shares of the company's stock, valued at approximately $657,000.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Van ECK Associates Corp boosted its stake in Twist Bioscience by 56.4% during the fourth quarter. Van ECK Associates Corp now owns 740 shares of the company's stock worth $34,000 after buying an additional 267 shares during the period. Banque Transatlantique SA purchased a new position in shares of Twist Bioscience during the 4th quarter worth about $43,000. US Bancorp DE raised its holdings in shares of Twist Bioscience by 72.0% in the fourth quarter. US Bancorp DE now owns 1,436 shares of the company's stock worth $67,000 after buying an additional 601 shares during the period. KBC Group NV lifted its stake in shares of Twist Bioscience by 71.4% during the 4th quarter. KBC Group NV now owns 2,942 shares of the company's stock worth $137,000 after acquiring an additional 1,226 shares during the last quarter. Finally, Teza Capital Management LLC purchased a new position in Twist Bioscience during the 4th quarter valued at $204,000.

Twist Bioscience Stock Performance

Twist Bioscience stock traded up $0.10 during mid-day trading on Monday, reaching $28.26. 781,842 shares of the company traded hands, compared to its average volume of 977,464. Twist Bioscience Co. has a fifty-two week low of $27.12 and a fifty-two week high of $60.90. The firm's fifty day moving average is $36.71 and its two-hundred day moving average is $42.81. The company has a debt-to-equity ratio of 0.03, a current ratio of 4.96 and a quick ratio of 4.62. The company has a market capitalization of $1.69 billion, a price-to-earnings ratio of -8.36 and a beta of 2.54.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last issued its earnings results on Monday, May 5th. The company reported ($0.66) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.56) by ($0.10). The firm had revenue of $92.79 million during the quarter, compared to analysts' expectations of $92.00 million. Twist Bioscience had a negative return on equity of 32.69% and a negative net margin of 59.76%. On average, equities research analysts expect that Twist Bioscience Co. will post -2.12 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, COO Patrick John Finn sold 1,877 shares of the stock in a transaction dated Wednesday, May 21st. The shares were sold at an average price of $29.75, for a total transaction of $55,840.75. Following the sale, the chief operating officer now directly owns 240,783 shares of the company's stock, valued at $7,163,294.25. This represents a 0.77% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Adam Laponis sold 936 shares of the firm's stock in a transaction dated Wednesday, May 21st. The shares were sold at an average price of $29.75, for a total value of $27,846.00. Following the sale, the chief financial officer now owns 106,018 shares in the company, valued at $3,154,035.50. This trade represents a 0.88% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 26,011 shares of company stock valued at $951,499 over the last ninety days. Company insiders own 3.01% of the company's stock.

Wall Street Analyst Weigh In

A number of equities analysts have commented on the stock. Guggenheim restated a "buy" rating and issued a $50.00 target price on shares of Twist Bioscience in a research note on Tuesday, May 6th. Scotiabank restated an "outperform" rating on shares of Twist Bioscience in a report on Tuesday, February 4th. The Goldman Sachs Group cut their price target on Twist Bioscience from $55.00 to $48.00 and set a "buy" rating on the stock in a report on Tuesday, May 6th. Barclays decreased their price objective on Twist Bioscience from $58.00 to $45.00 and set an "overweight" rating for the company in a research note on Thursday, April 10th. Finally, JPMorgan Chase & Co. reduced their target price on shares of Twist Bioscience from $40.00 to $33.00 and set an "underweight" rating for the company in a report on Tuesday, May 6th. One analyst has rated the stock with a sell rating, one has given a hold rating and eight have assigned a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $50.40.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.